SNYR vs XTLB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SNYR exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.26, indicating negative shareholders' equity. The company is experiencing a collapse in top-line growth with revenue declining 41% YoY and a catastrophic Q/Q EPS growth of -3600%. Despite a 'strong_buy' analyst consensus and a target price of $6.25, the fundamental data shows a company in a death spiral with a 78.9% one-year price decline and zero earnings beats in the last four quarters.
XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.
Compare Another Pair
Related Comparisons
SNYR vs XTLB: Head-to-Head Comparison
This page compares Synergy CHC Corp. (SNYR) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.